Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.
about
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychoticsPharmacogenetics of antipsychotics.Genetic variation in melatonin pathway enzymes in children with autism spectrum disorder and comorbid sleep onset delay.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.CYP1A2 polymorphism -1545C > T (rs2470890) is associated with increased side effects to clozapine.Clinical pharmacology of atypical antipsychotics: an update.Genetic and Clinical Factors Affecting Plasma Clozapine ConcentrationPharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update.The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review.PharmGKB summary: very important pharmacogene information for CYP1A2.Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.Pharmacogenetics in psychiatry: are we ready for widespread clinical use?Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.PhRMA white paper on ADME pharmacogenomics.Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs.Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.Pharmacogenetic considerations in the treatment of psychiatric disorders.Factors affecting interindividual differences in clozapine response: a review and case report.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.Pharmacological management of acute and persistent aggression in forensic psychiatry settings.Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.Pharmacogenetics in schizophrenia: a review of clozapine studies.Clinical applications of CYP genotyping in psychiatry.Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia.Genetic Determinants of Clozapine-Induced Metabolic Side Effects.Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.Clozapine: more than 900 mg/day may be needed.The significance of sampling time in therapeutic drug monitoring of clozapine.Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertensionClozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and AgranulocytosisImpact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and InducibilityCYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia
P2860
Q28079065-F28B1776-1782-47F5-9EA8-35E9924FDEA5Q33836837-FB7A146B-99FB-499C-9277-E7828DA5B350Q34430684-B8241C0B-6857-4D0C-BEDD-A763543E0AB6Q35015993-6E2BFFE8-1D5D-4AB0-8DDA-0D2E8ECFF2CEQ35098697-73C6A87B-00BE-483E-8B3D-C2A556F0CBC9Q35728228-19684BF2-91D4-4178-9E4E-EBDC9FAB9065Q35746655-06114CEF-60B8-4636-AE1E-6F487B514119Q35771833-23224ADF-FAFE-491E-A0FE-2E9AC99C89E1Q35857645-3A04AED8-2206-4DB7-84CC-73A6614ADDEFQ35940452-E645484B-DCF8-4673-B91C-6E002E999119Q36522045-3C07ECA0-74F3-4207-BCC7-F10501923078Q37076472-613A0225-DBBD-436F-8B0A-A45768DA75D2Q37157901-DF132382-F6E3-461D-B56E-19D03D68DE02Q37182212-19DC3F29-9EE5-47CF-AA4A-7DD1587BE049Q37344778-B4699E08-26FF-4E78-8747-428BB615C840Q37344782-2BD75868-1E8F-4CE9-B8D1-8A324D554834Q37378059-C2F7C2AF-7AD7-4FBB-B96D-3932244BBF7BQ37542607-DB5A5484-9B34-4055-AAF7-D8CC86B3F669Q37681573-1090F69D-C73F-4DC5-94A1-3AA95B81DE71Q37860249-00AB5A33-B6F5-4142-81F1-0C4BB5B39EB4Q37952823-A1787DA3-1E31-4C01-B745-2E86F6967A18Q37960512-F24CA590-88C2-4C89-8239-0103DAF721AFQ37963568-B7214AF5-7ACE-4278-A28D-3B39FE27E567Q38099224-FCE799D0-4DCC-42A1-BC75-7FEEDCD2CA08Q38154175-1EE344AD-F317-4B7D-AE5A-FB4DE7F1530EQ38247063-C88DC79F-02E2-43AD-A563-8ECDE87FBFBFQ39476490-DD506314-8EB2-4DC3-938C-2F19CFB64325Q40562486-C8B515F1-D131-4CF6-8490-F0BB4752CB36Q46007459-DDB9542D-E836-4F95-A80D-CEDF251B5B70Q46565038-83DA82F6-DEB7-4E1F-AD08-5E03B5C3C40DQ51026132-1E894496-66E9-4B0B-91D4-A5B8C9FFBF05Q57398058-B03A012E-883A-4E05-889C-7AD60E085630Q57491589-584616D2-2348-43C2-B903-9039F6239911Q57550190-9BA6937C-4CF4-4501-B053-52653333152EQ57820328-479DCAC8-D555-4CD6-B340-2FEDB9D23BB9
P2860
Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Nonresponse to clozapine and u ...... a and analysis of CYP1A2 gene.
@ast
Nonresponse to clozapine and u ...... a and analysis of CYP1A2 gene.
@en
type
label
Nonresponse to clozapine and u ...... a and analysis of CYP1A2 gene.
@ast
Nonresponse to clozapine and u ...... a and analysis of CYP1A2 gene.
@en
prefLabel
Nonresponse to clozapine and u ...... a and analysis of CYP1A2 gene.
@ast
Nonresponse to clozapine and u ...... a and analysis of CYP1A2 gene.
@en
P2093
P1476
Nonresponse to clozapine and u ...... a and analysis of CYP1A2 gene.
@en
P2093
Delphine Allorge
E Jaquenoud Sirot
Franck Broly
Gianni Cucchia
Michèle Jonzier-Perey
Pierre Baumann
Stefan Bender
P304
P356
10.1097/01.JCP.0000116646.91923.2F
P407
P50
P577
2004-04-01T00:00:00Z